Page 16 - Read Online

Calais da Silva et al. Systemic humoral responses during BCG treatment

Patient consent expression. J Clin Oncol 1996;14:1778-86.
Patients entered this study after written informed 15. Videira PA, Ligeiro D, Correia M, Trindade H. Gene expression
consent and were analyzed anonymously. analysis in superficial bladder cancer: comparison of two suitable
endogenous reference genes. Curr Urol 2007;1:145-50.
Ethics approval 16. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder
cancer. Res Rep Urol 2015;7:65-79.
The study has been approved by the ethical committee 17. Severino PF, Silva M, Carrascal MA, Calais F, Dall’Olio F, Videira
of the Hospital. All procedures followed the universal PA. Bladder cancer -- glycosylation insights. Carbohydr Chem
bioethical principles (Universal Declaration on 2012;38:156-75.
Bioethics and Human Rights of UNESCO, 19 October 18. Chen X, O’DONNELL MA, Luo Y. Dose-dependent synergy of Th1-
2005; The Charter of Fundamental rights of the EU, stimulating cytokines on bacille Calmette-Guerin-induced interferon-
2000; Ethical principles for medical research involving gamma production by human mononuclear cells. Clin Exp Immunol
2007;149:178-85.
human subjects - Declaration of Helsinki (2008) with 19. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou
2013 amendments. CC, Chopin DK. Prognostic value of a T helper 1 urinary cytokine
response after intravesical bacillus Calmette-Guerin treatment for
REFERENCES superficial bladder cancer. J Urol 2002;167:364-7.
20. Valentini CG, Bozzoli V, Larici AR, Larocca LM, Delogu G, Leone
1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou- G, Pagano L. Systemic granulomatous reaction secondary to treatment
Redorta J, Rouprêt M; European Association of Urology (EAU). of bladder cancer with bacillus calmette-guerin. Mediterr J Hematol
EAU guidelines on non-muscle-invasive urothelial carcinoma of the Infect Dis 2012;4:e2012040.
bladder, the 2011 update. Eur Urol 2011;59:997-1008. 21. Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T,
2. Tishler M, Shoenfeld Y. BCG immunotherapy -- from pathophysiology Kanetake H, Saito Y. Systemic immune response after intravesical
to clinical practice. Expert Opin Drug Saf 2006;5:225-9. instillation of bacille Calmette-Guérin (BCG) for superficial bladder
3. Lima L, Severino PF, Silva M, Miranda A, Tavares A, Pereira S, cancer. Clin Exp Immunol 1999;115:131-5.
Fernandes E, Cruz R, Amaro T, Reis CA, Dall’Olio F, Amado F, 22. Coussens LM, Werb Z. Inflammation and cancer. Nature
Videira PA, Santos L, Ferreira JA. Response of high-risk of recurrence/ 2002;420:860-7.
progression bladder tumours expressing sialyl-Tn and sialyl-6-T to 23. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection,
BCG immunotherapy. Br J Cancer 2013;109:2106-14. inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-65.
4. Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L. Predictive 24. Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y,
biomarkers of bacillus calmette-guérin immunotherapy response in Malats N. Inflammatory biomarkers and bladder cancer prognosis: a
bladder cancer: where are we now? Adv Urol 2012;2012:232609. systematic review. Eur Urol 2014;66:1078-91.
5. Videira PA. Sweet side of bladder cancer. World J Clin Urol 25. Hawkyard SJ, Jackson AM, James K, Prescott S, Smyth JF, Chisholm
2015;4:104-7. GD. The inhibitory effects of interferon gamma on the growth of
6. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette- bladder cancer cells. J Urol 1992;147:1399-403.
Guerin in the treatment of superficial bladder tumors. J Urol 26. Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin
1976;116:180-3. Cancer Res 2011;17:6118-24.
7. Videira PA, Calais FM, Correia M, Ligeiro D, Crespo HJ, Calais F, 27. Yim MS, Ha YS, Kim IY, Yun SJ, Choi YH, Kim WJ. HMOX1 is an
Trindade H. Efficacy of bacille Calmette-Guérin immunotherapy important prognostic indicator of nonmuscle invasive bladder cancer
predicted by expression of antigen-presenting molecules and recurrence and progression. J Urol 2011;185:701-5.
chemokines. Urology 2009;74:944-50. 28. Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek
8. Böhle A. BCG’s mechanism of action -- increasing our understanding. C, Jocham D, Flad HD, Böhle A. Perforin-mediated lysis of tumor
For the EBIN Group. Eur Urol 2000;37 Suppl 1:1-8. cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated
9. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin killer cells. Clin Cancer Res 2000;6:3729-38.
immunotherapy for superficial bladder cancer. J Urol 2003;170:964-9. 29. Ernst WA, Thoma-Uszynski S, Teitelbaum R, Ko C, Hanson DA,
10. Alexandroff AB, Nicholson S, Patel PM, Jackson AM. Recent Clayberger C, Krensky AM, Leippe M, Bloom BR, Ganz T, Modlin
advances in bacillus Calmette-Guerin immunotherapy in bladder RL. Granulysin, a T cell product, kills bacteria by altering membrane
cancer. Immunotherapy 2010;2:551-60. permeability. J Immunol 2000;165:7102-8.
11. Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette-Guerin- 30. Bidnur S, Savdie R, Black PC. Inhibiting immune checkpoints for the
induced macrophage cytotoxicity against bladder cancer cells. Clin treatment of bladder cancer. Bladder Cancer 2016;2:15-25.
Dev Immunol 2010;2010:357591. 31. Sander B, Damm O, Gustafsson B, Andersson U, Håkansson L.
12. Toossi Z, Hirsch CS, Wu M, Mayanja-Kizza H, Baseke J, Thiel B. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder
Distinct cytokine and regulatory T cell profile at pleural sites of tumors treated with intravesical bacillus Calmette-Guerin. J Urol
dual HIV/tuberculosis infection compared to that in the systemic 1996;156:536-41.
circulation. Clin Exp Immunol 2011;163:333-8. 32. De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo
13. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S. E, De Groot ER, Van der Meijden AP, Vegt PD, Debruyne FM,
Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a Ruitenberg EJ. Induction of urinary interleukin-1 (IL-1), IL-2, IL-
parameter of immunological dysfunction in patients of superficial 6, and tumour necrosis factor during intravesical immunotherapy
transitional cell carcinoma of bladder. Cancer Immunol Immunother with bacillus Calmette-Guérin in superficial bladder cancer. Cancer
2006;55:734-43. Immunol Immunother 1992;34:306-12.
14. Kaempfer R, Gerez L, Farbstein H, Madar L, Hirschman O, 33. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, Messina
Nussinovich R, Shapiro A. Prediction of response to treatment in A, Peschle C, De Maria R. IL-4 protects tumor cells from anti-CD95
superficial bladder carcinoma through pattern of interleukin-2 gene and chemotherapeutic agents via up-regulation of antiapoptotic
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ July 14, 2017 125